VBI VACCINES INC (VBIV) Stock Price, Quote, News and Overview
NASDAQ:VBIV - Nasdaq - CA91822J2020 - Common Stock - Currency: USD
VBIV Quote, Performance and Key Statistics
0.0653
-0.07 (-50.87%)
The current stock price of VBIV is 0.0653 USD. In the past month the price decreased by -91.32%. In the past year, price decreased by -94.82%.
VBIV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About VBIV
Company Profile
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2001-11-19. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Company Info
VBI VACCINES INC
160 Second Street, Cambridge
Cambridge MASSACHUSETTS 02142 US
CEO: Jeffrey Baxter
Employees: 131
Company Website: https://www.vbivaccines.com/
Phone: 16178303031
VBI VACCINES INC / VBIV FAQ
What is the stock price of VBI VACCINES INC today?
The current stock price of VBIV is 0.0653 USD. The price decreased by -50.87% in the last trading session.
What is the ticker symbol for VBI VACCINES INC stock?
The exchange symbol of VBI VACCINES INC is VBIV and it is listed on the Nasdaq exchange.
On which exchange is VBIV stock listed?
VBIV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VBI VACCINES INC stock?
7 analysts have analysed VBIV and the average price target is 5.1 USD. This implies a price increase of 7710.11% is expected in the next year compared to the current price of 0.0653. Check the VBI VACCINES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VBI VACCINES INC worth?
VBI VACCINES INC (VBIV) has a market capitalization of 1.87M USD. This makes VBIV a Nano Cap stock.
How many employees does VBI VACCINES INC have?
VBI VACCINES INC (VBIV) currently has 131 employees.
Is VBI VACCINES INC (VBIV) expected to grow?
The Revenue of VBI VACCINES INC (VBIV) is expected to decline by -2.62% in the next year. Check the estimates tab for more information on the VBIV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VBI VACCINES INC (VBIV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VBIV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VBIV, evaluating the profitability, health, valuation and growth aspects
- VBI VACCINES INC (VBIV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VBI VACCINES INC (VBIV) Sales and EPS estimates to see what analysts future expectations are.
- VBI VACCINES INC (VBIV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VBI VACCINES INC (VBIV) Insider and Institutional Ownership to learn about the owners and their transactions.
- VBI VACCINES INC (VBIV) Stock Chart to make your own analysis
- VBI VACCINES INC (VBIV) Latest news and press-releases to stay up to date.
Does VBI VACCINES INC (VBIV) stock pay dividends?
VBIV does not pay a dividend.
When does VBI VACCINES INC (VBIV) report earnings?
VBI VACCINES INC (VBIV) will report earnings on 2024-11-12, before the market open.
What is the Price/Earnings (PE) ratio of VBI VACCINES INC (VBIV)?
VBI VACCINES INC (VBIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.8).
VBIV Technical Analysis
VBIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VBIV. VBIV has a bad profitability rating. Also its financial health evaluation is rather negative.
VBIV Financial Highlights
Over the last trailing twelve months VBIV reported a non-GAAP Earnings per Share(EPS) of -6.8. The EPS decreased by -90.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VBIV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to VBIV. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 86.5% and a revenue growth -2.62% for VBIV